Good MorningEquities hovered near break even on Thursday following another decline in the Index of Leading Indicators. The index fell-0.4% in the Month of July making it the 4th straight month of decline but there is some good news. The -0.4% is a better read than the -0.5% indicated by the consensus estimate and an improvement from the prior months -0.7%. If this turns into a trend economic expansion could be back on the table by the end of the quarter but it is too soon to tell.
Next week could be a tough one for the market. There are very few earnings reports on the schedule but at least one major economic report that could move the market. The PCE price index is due out on Friday and will give the latest read on consumer inflation. A better-than-expected report will send the market higher. Featured: Get our #1 crypto pick within minutes (Ad) 
|
Healthcare | | Pharmaceutical stocks are frequently subject to whiplash trade, and that’s evident now with sharp moves lower in names such as Sanofi (NASDAQ: SNY), GSK (NYSE: GSK), and Teva Pharmaceuticals (NYSE: TEVA).
Price swings in that industry are often determined by the results of clinical trials or... Read the Full Story |
|
From Our Partners | | Most people’s first crypto purchase is their worst one. Not because crypto is bad. Because they make the same handful of mistakes almost everyone makes. They pay too much, because they don’t know how to buy at lower prices.
Crypto Revolution, our book with a foreword by Kevin Harrington from ABC’s Shark Tank, shows you how to spot real opportunities instead of chasing hype.
Everything is digital and available the moment you claim it. | | Download Crypto Revolution now. |
|
Industrials | | If you’ve ever gotten a speed, red light, or school bus camera ticket in the mail, then you know how miserable they can be. At some point, you think to yourself that there’s got to be someone on the other side making a ton of money off these tickets. Well, there is a company making a ton... Read the Full Story |
|
Consumer Discretionary | |
The institutional support for TJX Companies (NYSE: TJX) remains high at 91.5% but their activity may cap gains in the near term. The institutions have been net-sellers for the last two consecutive quarters and that trend may not end with the Q2 earnings report. While the selling is light at only $... Read the Full Story |
|
From Our Partners | | The biggest IPO in history is likely just weeks away…
Anthropic, the company behind Claude AI, is rumoured to be lining up a Nasdaq debut before Thanksgiving… at a valuation of up to $2 trillion. But here’s what nobody’s talking about…
A raise of about $100 billion doesn’t just make headlines. It puts an enormous spotlight on the AI industry. And as investors rush to find the next big opportunity in artificial intelligence, some of the most interesting plays may be hiding outside traditional AI stocks. | | Click here to see my #1 pick for the Claude IPO. |
|
Consumer Discretionary | |
I have a background in marketing. So it’s impossible for me to ignore the loyalty that Starbucks (NASDAQ:SBUX) receives from its customers. It shows up in my social media feed for sure. But I also notice that, even in the small-ish area I live in, Starbucks continues to expand, or at least r... Read the Full Story |
|
Consumer Staples | |
BJ’s (NYSE: BJ) Wholesale Club Q2 results echo the strength seen in Sam’s Club segment at Walmart (NYSE: WMT). The two membership clubs posted record results driven by rising member counts that are underpinning a robust outlook for the year. Assuming these trends are true across the di... Read the Full Story |
|
From Our Partners | | After the Dot-Com Bubble burst in March 2000, the Nasdaq fell 78% over the following decade. But gold staged a historic bull run, and select miners delivered gains of 50X, 53X, 252X, and even 362X.
Garrett Goggin, CFA, CMT and founder of The Golden Portfolio, has spent over 20 years studying these market rotations, including 15 years working alongside gold analyst John Doody. He's identified four gold miners positioned for the next rotation out of AI stocks. | | See Garrett Goggin's four gold miner picks before the next rotation begins |
|
Technology | |
When it comes to the tech world there’s established, blue-chip tech and then there’s experimental tech and Cisco Systems (NASDAQ: CSCO) is as established as a company can be. The company manufactures, markets, and services IP-based networking, routing, and infrastructure components use... Read the Full Story |
|
Technology | | It’s been a rollercoaster of a summer for Micron (NASDAQ: MU) investors, who’ve had to watch their shares fall 30% and then rally 30% in the past two months alone. But there are signs that the worst of the volatility might now be behind them. This will be a welcome turn of events for all... Read the Full Story |
|
Technology | | ON Semiconductor (NASDAQ: ON) has taken a leadership role within its industry lately, as the stock notched gains of 26.11% in the past month and 28.21% in the past three months.
Other large-cap chip companies, such as Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD) have shown fundam... Read the Full Story |
|
Materials | | Metal miner Rio Tinto (NYSE: RIO) is up 7.8% since reporting first-half earnings in late July. Earnings declined 29%, to $2.73 per share, while revenue dropped 10% to $14.9 billion.
Although that was actually an earnings beat, the company also slashed its dividend in response to lower iron ore pri... Read the Full Story |
|
Industrials | |
If you've ever had an interest in business aviation, combat vehicles, weapons systems and munitions or shipbuilding and ship repair, General Dynamics Corporation (NYSE: GD) might be right up your alley.
General Dynamics pays an annual dividend of $5.04 per share and has a dividend yield of 2.1%.... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. | | View Today's Stock Pick |
|
